Found: 29
Select item for more details and to access through your institution.
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-021-01842-9
- By:
- Publication type:
- Article
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
- Published in:
- Science Signaling, 2016, v. 9, n. 415, p. 1, doi. 10.1126/scisignal.aac4374
- By:
- Publication type:
- Article
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
- Published in:
- Science Signaling, 2016, v. 9, n. 415, p. 1, doi. 10.1126/scisignal.aac4380
- By:
- Publication type:
- Article
Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
- Published in:
- Molecular Cancer, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12943-015-0346-9
- By:
- Publication type:
- Article
First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
- Published in:
- PLoS ONE, 2015, v. 10, n. 11, p. 1, doi. 10.1371/journal.pone.0143082
- By:
- Publication type:
- Article
Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0075414
- By:
- Publication type:
- Article
The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0059380
- By:
- Publication type:
- Article
A Bayesian machine learning approach for drug target identification using diverse data types.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-12928-6
- By:
- Publication type:
- Article
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12 , 2436.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2436, doi. 10.3390/cancers12092436
- By:
- Publication type:
- Article
Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 2, p. 252, doi. 10.1002/cam4.198
- By:
- Publication type:
- Article
Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 3, p. 400, doi. 10.1093/neuonc/noaa188
- By:
- Publication type:
- Article
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 1, p. 94, doi. 10.1093/neuonc/noz164
- By:
- Publication type:
- Article
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
- Published in:
- Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac143
- By:
- Publication type:
- Article
Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-83215-y
- By:
- Publication type:
- Article
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 171, p. 1, doi. 10.1126/scitranslmed.3004828
- By:
- Publication type:
- Article
Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
- Published in:
- PLoS ONE, 2016, v. 11, n. 2, p. 1, doi. 10.1371/journal.pone.0149365
- By:
- Publication type:
- Article
Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.789450
- By:
- Publication type:
- Article
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S165, doi. 10.1093/neuonc/noae021
- By:
- Publication type:
- Article
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S173, doi. 10.1093/neuonc/noae031
- By:
- Publication type:
- Article
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S155, doi. 10.1093/neuonc/noae001
- By:
- Publication type:
- Article
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 8, p. 1219, doi. 10.1093/neuonc/noac086
- By:
- Publication type:
- Article
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
- Published in:
- Journal of Neurosurgery, 2019, v. 23, n. 6, p. 719, doi. 10.3171/2019.2.PEDS18480
- By:
- Publication type:
- Article
Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022).
- Published in:
- Advanced Materials, 2022, v. 34, n. 2, p. 1, doi. 10.1002/adma.202270014
- By:
- Publication type:
- Article
Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.
- Published in:
- Advanced Materials, 2022, v. 34, n. 2, p. 1, doi. 10.1002/adma.202100096
- By:
- Publication type:
- Article
ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.577141
- By:
- Publication type:
- Article
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
- Published in:
- PLoS ONE, 2017, v. 12, n. 8, p. 1, doi. 10.1371/journal.pone.0180541
- By:
- Publication type:
- Article